An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

• Status: Completed
• Trial end date: 2006-07-31
• Target enrollment: 0
• Participant gender: All

Summary

A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL).

• Stable disease or better for at least 3 months on most recent treatment

• Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study

• Adequate blood testing, liver, and kidney function as required by the study.

• Eligible subjects will allow tissue samples to be examined and stored.

Exclusion Criteria:

• Patient has been treated with other investigational agents with a similar anti-tumor mechanism.

• Patient should not have failed more than 3 prior treatment regimens.